This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, March 7, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (
www.apricusbio.com) announced today that Edward Cox, Vice President Corporate Development & Investor Relations, will present at the BIO-Europe Spring 2013 Partnering Conference, being held in Barcelona, Spain. Mr. Cox's presentation will take place on Wednesday, March 13, 2013 at 11:00 a.m. Local Time (6:00 a.m. Eastern Time).
A replay of the presentation will be accessible to the public online at the Company's website at
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros®, for the treatment of erectile dysfunction, which will be marketed in Canada by Abbott Laboratories and Femprox®, a product candidate, for the treatment of female sexual arousal disorder, which successfully completed one 400-patient Phase III study in China.
For further information on Apricus Bio, visit
http://www.apricusbio.com. You can also receive information at
CONTACT: Apricus Bio Investor Relations: